Download Free Performance Of Pharmaceutical Companies In India Book in PDF and EPUB Free Download. You can read online Performance Of Pharmaceutical Companies In India and write the review.

This book explains how government support and institutional set up facilitated the evolution of the Indian pharmaceutical industry and provides an economic analysis of firm strategies due to recent policy changes. The book is useful for researchers interested in understanding the transition of a lifeline sector for an emerging economy like India. Students of public policy, health administrators and health economists who are interested in the functioning of the pharmaceutical sector that produces life saving drugs in developing nations will find this book useful. The book also provides good coverage on data envelopment analysis (DEA), a useful technique for understanding productivity and efficiency. It can provide guidance to the research students on the applicability of DEA technique to address various research questions for analysis. The book will be a valuable addition to libraries in colleges of pharmacy and medicine as well as to all other academic and research centers.
The book provides insight into different research and development (R&D) activities performed by Indian pharmaceutical companies. It describes how R&D activities have evolved in the last three decades on Indian soil. The book discusses how emerging economy like India has become the ‘Pharmacy of the World’ and how reputed and research-centric Indian drug manufacturing companies are aligning their business model by incepting the business idea as ‘Innovate in India and Serve to the World’. Subsequently, through successful implementation of the R&D activities and endeavors, Indian pharmaceutical companies have been witnessing different drug discoveries and innovations which have been performed in an indigenous manner. Contemporary marketing strategies adopted by the research-centric Indian pharmaceutical companies for selling innovative drug products across the globe, attaining global competitiveness, and maintaining a seamless supply chain through export initiatives have also been discussed in this book. Finally, the book figures out the relationship between R&D and financial performance with the help of panel data analysis (PDA), an econometric approach.
This open access book analyses intellectual property codification and innovation governance in the development of six key industries in India and China. These industries are reflective of the innovation and economic development of the two economies, or of vital importance to them: the IT Industry; the film industry; the pharmaceutical industry; plant varieties and food security; the automobile industry; and peer production and the sharing economy. The analysis extends beyond the domain of IP law, and includes economics and policy analysis. The overarching concern that cuts through all chapters is an inquiry into why certain industries have developed in one country and not in the other, including: the role that state innovation policy and/or IP policy played in such development; the nature of the state innovation policy/IP policy; and whether such policy has been causal, facilitating, crippling, co-relational, or simply irrelevant. The book asks what India and China can learn from each other, and whether there is any possibility of synergy. The book provides a real-life understanding of how IP laws interact with innovation and economic development in the six selected economic sectors in China and India. The reader can also draw lessons from the success or failure of these sectors.
This book evaluates the performance of the Indian pharmaceutical industry, which plays an important role in economic development. It highlights the role the government has had in facilitating the growth of the industry from non-existence, before the 1970s, to being one of the largest pharmaceutical industries in the world today. The text employs various useful techniques to provide an understanding of productivity and efficiency, such as data envelopment analysis, stochastic frontier analysis, the Malmquist Productivity Index and the Hicks-Moorsteen Productivity Index. The book will be useful to health administrators, students of public policy, and health economists with an interest in the pharmaceutical sector.
GLOBAL PHARMACEUTICAL INDUSTRY The global pharmaceutical industry is worth US$ 300 billion a year, a figure projected to grow within three years to US$ 400 billion. The 10 biggest drug firms control more than one-third of this market, many with annual revenue of \ more than US$ 10 billion and profit margins of about 30%. Six are based in the \sUSA and four are based in Europe. North and South America, Europe, and Japan are expected to continue to account for a complete 85% of the global pharmaceutical market well into the 21st century. At present, businesses spend one-third of their sales income on selling their goods - nearly double what they spend on research and growth.
The pharmaceutical industry in India is one of the largest and most advanced among the developing countries. During the last three decades, Indian pharmaceutical industry achieved spectacular progress by any standard. India s pharmaceutical industry has b
This book explains how government support and institutional set up facilitated the evolution of the Indian pharmaceutical industry and provides an economic analysis of firm strategies due to recent policy changes. The book is useful for researchers interested in understanding the transition of a lifeline sector for an emerging economy like India. Students of public policy, health administrators and health economists who are interested in the functioning of the pharmaceutical sector that produces life saving drugs in developing nations will find this book useful. The book also provides good coverage on data envelopment analysis (DEA), a useful technique for understanding productivity and efficiency. It can provide guidance to the research students on the applicability of DEA technique to address various research questions for analysis. The book will be a valuable addition to libraries in colleges of pharmacy and medicine as well as to all other academic and research centers.
This book provides a mechanism which improves the efficiency, transparency, accountability of the pharmaceutical companies and builds the confidence of the stakeholders. It also helps in finding the root causes for failure of some pharmaceutical companies and find an appropriate solution to improve their performance. This book may also be useful to researchers, policy makers, research bodies and pharmaceutical companies. This book is sure of good source of information to the readers in general and the students and future researchers at large in particular.
Financial performance is a subjective measure of how well a firm can use assets from its primary mode of business and generate revenues. This term is also used as a general measure of a firm's overall financial health over a given period of time, and can be used to compare similar firms across the same companies or to compare companies or sectors in aggregation. A firm's performance measurement has been the subject matter of discussion for decision makers as managers, planners, economists and academic staff since long many years. Financial analysts often assess firm's production and productivity performance, profitability performance, liquidity performance, leverage performance, asset utilisation performance and growth performance. The financial performance analysis identifies the financial strengths and weaknesses of the firm by properly establishing relationships between the items of the balance sheet and profit and loss account. In this context researcher has undertaken an analysis of financial performance of pharmaceutical companies to understand how management of finance plays a crucial role in the growth. In this paper an attempt has been made to analyse the profitability position of five leading pharmaceutical companies of India with the help of mean, standard deviation, co-efficient of variation, multiple regression, and analysis of variance. The increase in profitability will not only yield greater efficiency but also improve financial performance in future. The study is conducted by taking into account of the data for five years from 2011-2012 to 2015-2016. The Pharmaceutical companies selected for study are Lupin, Wochkardt, Glenmark, Abott and Torrent. The financial performance of these companies are evaluated and found that the profitability of the selected pharmaceutical companies in India during the study period is satisfactory.
Some papers presented at a conference held at Hyderabad in September 2010.